Alopecia areata Learning Zone
Transcript: The ALLEGRO clinical trial
Dr Brittany Craiglow
Interview recorded Mar 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So the ALLEGRO clinical trial was looking at the medication ritlecitinib, which is a JAK3/TEC inhibitor, and we have data. Their primary endpoint was at 24 weeks. So that's one thing with clinical trials in alopecia areata that is different from atopic dermatitis or psoriasis. We're looking at endpoints that are much farther out, and that's because hair takes a long time to grow. So in this clinical trial, importantly, it enrolled at both adults and adolescents, so it enrolled patients all the way down to 12 years of age. And we've seen approvals in that adolescent age group also, which is really exciting 'cause those patients, you know, really, there's been a huge unmet need there. So patients had to have at least 50% scalp hair loss to be in the trial. And then the primary endpoint was looking at the percent of patients who got to a SALT score, which is the Severity of Alopecia Tool, which is just a measure of how much of the scalp is involved in hair loss, so by 24 weeks, what percent of patients got to a SALT score of 20 or less, so meaning 20% or less hair loss, or you could think about it as 80% or more coverage.
And so by 24 weeks, about 23% of patients hit that endpoint. But then at 24, when you look at the slope of the curve, not surprisingly, it's, you know, creeping up, right? And so if you take those patients, and you look at them longer term, many more patients achieve the endpoint. So if you double the time to 48 weeks, you get about 43% of patients meeting that endpoint. And there, the slope of the curve is still kind of going up. So some patients just take longer to achieve that endpoint. So really exciting. You know, similar results to what we've seen from other clinical trials. And I think importantly for ritlecitinib, you know, having that adolescent indication is really huge and is gonna change clinical practise. And again, knowing that we have this sort of window of opportunity, we have patients who, before there was an approval in adolescents, they may have sort of really lost their chance of having hair if we weren't able to treat them now. So this is a really big breakthrough in alopecia areata, and I think, you know, it will be really fun to be able to see some of these adolescents really get their life back.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, who has reviewed the content only for scientific accuracy. EPG Health received funding from the sponsor in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content.